Literature DB >> 6357106

Effect of low dose 1 alpha-hydroxycholecalciferol on glomerular filtration rate in moderate renal failure.

F U Eke, M H Winterborn.   

Abstract

Serial measurements of 51Cr edetic acid clearance were made over a period of one year in two groups of 8 children, in a double blind trial of 1 alpha-hydroxycholecalciferol (10 ng/kg/day) and calciferol (670 ng/kg/day). Glomerular filtration rate (GFR) at the beginning of the trial was 20-50 ml/min/1.73 m2; it rose in the children given 1 alpha-hydroxycholecalciferol (group A) after 6 months but was not appreciably different from the pretreatment value after 12 months. The GFR in the children given calciferol (group B) showed no significant difference at 6 or 12 months. Parathyroid hormone values fell markedly in group A after 6 months but not in group B. Quantitative bone histology improved considerably in group A but not in group B at 12 months. Low dose 1 alpha-hydroxycholecalciferol may be used effectively for renal osteodystrophy in children with moderate but stable renal failure without jeopardising renal function.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6357106      PMCID: PMC1628291          DOI: 10.1136/adc.58.10.810

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  16 in total

1.  Renal osteodystrophy in nondialysed adolescents. Long-term treatment with 1alpha-hydroxycholecalciferol.

Authors:  J A Kanis; R G Henderson; G Heynen; J G Ledingham; R G Russell; R Smith; R J Walton
Journal:  Arch Dis Child       Date:  1977-06       Impact factor: 3.791

2.  Bone histology in incipient and advanced renal failure.

Authors:  H H Malluche; E Ritz; H P Lange; L Kutschera; M Hodgson; U Seiffert; W Schoeppe
Journal:  Kidney Int       Date:  1976-04       Impact factor: 10.612

3.  1alpha-Hydroxycholecalciferol in renal osteodystrophy.

Authors:  A M Pierides; H A Ellis; M K Ward; W Simpson; D N Kerr
Journal:  Calcif Tissue Res       Date:  1977-05

4.  Comparison of effects of 1 alpha-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 in man.

Authors:  A S Brickman; J W Coburn; G R Friedman; W H Okamura; S G Massry; A W Norman
Journal:  J Clin Invest       Date:  1976-06       Impact factor: 14.808

5.  Augmentation of arterial hepatic and renal flow by extracted and synthetic parathyroid hormone.

Authors:  G A Charbon; P F Hulstaert
Journal:  Endocrinology       Date:  1974-08       Impact factor: 4.736

6.  Effects of vitamin D metabolites and analogues on renal function.

Authors:  R B Naik; T Cundy; B H Robinson; R G Russell; J A Kanis
Journal:  Nephron       Date:  1981       Impact factor: 2.847

7.  A possible role for propranolol in the treatment of renal osteodystrophy.

Authors:  J F Caro; A Besarab; J F Burke; J A Glennon
Journal:  Lancet       Date:  1978-08-26       Impact factor: 79.321

8.  Impairment of renal function in patients on 1alpha-hydroxycholecalciferol.

Authors:  M H Winterborn; P J Mace; D A Heath; R H White
Journal:  Lancet       Date:  1978-07-15       Impact factor: 79.321

9.  Impairment of renal function in patients on 1alpha-hydroxycholecalciferol.

Authors: 
Journal:  Lancet       Date:  1978-08-19       Impact factor: 79.321

10.  Inhibition of parathyroid hormone secretion by 25-hydroxycholecalciferol and 24,25-dihydroxycholecalciferol in the dog.

Authors:  J M Canterbury; S Lerman; A J Claflin; H Henry; A Norman; E Reiss
Journal:  J Clin Invest       Date:  1978-05       Impact factor: 14.808

View more
  3 in total

1.  Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease Stages 2-5 and on dialysis.

Authors:  Rukshana Shroff; Mandy Wan; Evi V Nagler; Sevcan Bakkaloglu; Mario Cozzolino; Justine Bacchetta; Alberto Edefonti; Constantinos J Stefanidis; Johan Vande Walle; Gema Ariceta; Günter Klaus; Dieter Haffner; Claus Peter Schmitt
Journal:  Nephrol Dial Transplant       Date:  2017-07-01       Impact factor: 5.992

Review 2.  Interventions for metabolic bone disease in children with chronic kidney disease.

Authors:  Deirdre Hahn; Elisabeth M Hodson; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2015-11-12

Review 3.  Secondary hyperparathyroidism in children with chronic renal failure: pathogenesis and treatment.

Authors:  Cheryl P Sanchez
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.